1 / 24

Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases. Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan National Cancer Center, Tokyo Japan. Purpose.

paulos
Download Presentation

Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas:A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo Medial University, Sapporo Japan National Cancer Center, Tokyo Japan

  2. Purpose • To analyze expression patterns of EGFR, ERBB2, and KIT on 281 patients with common adult STS by standard immunohistochemical technique on formalin-fixed, paraffin-embedded sections • To Verify whether a significant association with prognosis is present

  3. Patients • 281 adult patients with common soft tissue sarcomas in the extremities and trunk diagnosed and treated • at the NCC, Tokyo, Japan • Histologic subtype • Fibrosarcoma (FS) 11 • Leiomyosarcoma (LMS)11 • Myxoid liposarcoma (LSM)52 • Well differentiated liposarcoma(LSW)50 • MPNST18 • Myxofibrosarcoma (MFS)53 • Pleomorphic MFH (PMFH)44 • Synovial sarcoma (SS)42

  4. Characteristic of 281 patients • Gender: 152 females and 129 males • Age: 10 to 85 years (median 50 yrs) • Treatment: • Resection All patients • Radiotherapy 25 • Chemotherapy 37 • Chemo + Radi 23

  5. Pathology reviewing, grade and Staging • Tumor typing • WHO Classification of Soft Tissue Tumors • Histologic grade • Differentiation, necrosis, MIB-1 index • TNM staging classification

  6. Primary Antibodies

  7. Evaluation of staining Strength Distribution 3+ and>10% = Positive 2+ 1+ or ≤10%= Negative 0

  8. Results

  9. Immunohistochemical Pattern

  10. Immunohistochemical Pattern

  11. Diffuse EGFR (3+) in MPNST Diffuse EGFR (2+) in leiomyosarcoma

  12. Focal ERBB2 (2+) in epithelioid cells of biphasic synovial sarcoma Diffuse EGFR (3+) in spindle cells of biphasic synovial sarcoma

  13. Focal KIT (2+) in spindle cells of monophasic synovial sarcoma

  14. EGFR (-) 79% EGFR (+) 64%

  15. Variables associated with patient survival: Univariate analysis • Stage • Histological grade • Depth • Size • Positive EGFR staining

  16. Variables associated with patient survival: Multivariate analysis • Stage • Histological grade • Depth • Size • Positive EGFR staining

  17. Kaplan-Meier survival curves stratified by EGFR status and by tumor size EGFR- 1.0 1.0 EGFR- .8 .8 EGFR+ .6 .6 EGFR+ .4 .4 p=0.03 .2 p=0.06 .2 0.0 0.0 0 10 20 30 40 50 60 70 0 10 20 30 40 50 60 70 Size 5-10cm (n=135) Size>10cm (n=77)

  18. Kaplan-Meier survival curves stratified by EGFR status and by histological grade 1.0 EGFR+ 1.0 EGFR+ .8 .8 EGFR- .6 .6 EGFR- .4 .4 p=0.08 p=0.7 .2 .2 0.0 0.0 0 10 20 30 40 50 60 70 0 10 20 30 40 50 60 70 Grade 2 (n=74) Grade 3 (n=111)

  19. Discussion

  20. Expression of EGFR in STSs

  21. Expression of ERBB2 and KIT • Merimsky et al. (2002) • No overexpression of ERBB2 in 230 STSs • Hornick et al. (2002) • Very limited expression of KIT in 365 STSs • This study • Limited expression of ERBB2 and KIT

  22. EGFR (-) 79% EGFR (+) 64%

  23. Target-specific agents and approaches for anticancer therapy IMC-C225 ABX-EGF Tyrosine kinase inhibitor Irresa

  24. Conclusion • We analyzed the expression of EGFR, ERBB2, and KIT in 281 patients with STS • Positive staining of EGFR: 168/281 (60%) • Positive staining of ERBB2, KIT was limited • EGFR overexpression was a negative prognostic factor associated with histological grade

More Related